Robert Mashal has bought NUVB on 2 days since Apr 2025
Director at Nuvation Bio Inc.
SEC CIK 0002007102 · Filings on SEC.gov ↗
Robert Mashal's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
2 filings since Apr 2025, newest first
About Robert Mashal
Dr. Robert Mashal is a biotechnology executive and board member who serves on the Board of Directors of Nuvation Bio Inc. (NYSE: NUVB), where he contributes strategic and clinical insight to the company’s oncology-focused biopharmaceutical portfolio.( He is a noted corporate insider at Nuvation Bio, with reported director-level trading activity in the company’s securities.( In parallel, he works as a consultant to the life sciences industry and is a Founder and Managing Director at Beacon Prince Partners, a biotechnology and life sciences consulting firm.(
Mashal’s career spans senior leadership, investment, and clinical roles across the biopharma sector. He previously served as Global Head of Strategy for the Immunology and Oncology franchises at Sanofi, and as CEO of NKT Therapeutics and Alinea Pharmaceuticals, both venture-backed life sciences companies.( Earlier, he was a partner at Boston Millennia Partners, sitting on the boards of GlycoFi, CardioMEMS, and Sapphire Therapeutics, and held a Program Executive role at Vertex Pharmaceuticals, where he participated in the Vertex–Novartis kinase collaboration.( He also worked as a consultant at McKinsey & Company and was previously a board-certified medical oncologist, training in internal medicine at the University of California, San Francisco and in oncology at the Dana-Farber Cancer Institute after earning both his B.A. and M.D. degrees from Johns Hopkins University.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.